This may be attributed to GPX4's modifications of N6-methyladenosine (m6A) and 5-methylcytosine (m5C), which activate STING and help maintain redox balance during cancer immunotherapy, thereby facilitating immune regulation 18. This evidence concerns the gene GPX4 and cancer.